for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Omeros Corporation

OMER.OQ

Latest Trade

15.86USD

Change

0.46(+2.99%)

Volume

121,523

Today's Range

15.18

 - 

15.91

52 Week Range

10.30

 - 

20.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Omeros Q2 Loss Per Share $0.29

Aug 8 (Reuters) - Omeros Corp <OMER.O>::ORATION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA.OMIDRIA REVENUES FOR 2Q 2019 WERE A RECORD HIGH AT $26.8 MILLION VERSUS $21.8 MILLION IN 1Q 2019.INVENTORY ON HAND AT WHOLESALERS AT JUNE 30, 2019 REMAINED CONSISTENT WITH HISTORICAL NORMS.

Omeros And Lonza Enter Long-Term Manufacturing Agreement For Commercial Supply Of Narsoplimab

July 31 (Reuters) - Omeros Corp <OMER.O>::OMEROS AND LONZA ENTER LONG-TERM MANUFACTURING AGREEMENT FOR COMMERCIAL SUPPLY OF NARSOPLIMAB.OMEROS CORP - OMEROS AND LONZA HAVE SUCCESSFULLY PARTNERED UNDER A MULTI-YEAR MANUFACTURING AGREEMENT FOR CLINICAL SUPPLY OF NARSOPLIMAB.OMEROS CORP - NEW MULTI-YEAR AGREEMENT SECURES A SOURCE OF COMMERCIAL QUANTITIES OF NARSOPLIMAB FOR USE FOLLOWING ANTICIPATED REGULATORY APPROVALS.OMEROS CORP - LONG-TERM MANUFACTURING AGREEMENT FOR COMMERCIAL PRODUCTION OF NARSOPLIMAB.

D. E. Shaw & Co Reports 5.0% Passive Stake In Omeros Corp

May 10 (Reuters) - D. E. Shaw & Co, L.P.: :D. E. SHAW & CO, L.P. REPORTS 5.0% PASSIVE STAKE IN OMEROS CORP AS OF APRIL 30 - SEC FILING.

D. E. Shaw & Co Reports 5.1 Percent Passive Stake In Omeros Corp As Of Feb 26, 2019

March 8 (Reuters) - Omeros Corp <OMER.O>::D. E. SHAW & CO REPORTS A PASSIVE STAKE OF 5.1 PERCENT IN OMEROS CORP AS OF FEB 26, 2019 - SEC FILING.

Omeros Reports Q4 Loss Per Share Of $0.48

March 1 (Reuters) - Omeros Corp <OMER.O>::ORATION REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.48.Q4 EARNINGS PER SHARE ESTIMATE $-0.81 -- REFINITIV IBES DATA.Q4 REVENUE $22 MILLION.Q4 REVENUE ESTIMATE $16.7 MILLION -- REFINITIV IBES DATA.AT DECEMBER 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AVAILABLE FOR OPERATIONS OF $60.5 MILLION.

Omeros Corp Streamlines Path To BLA For OMS721 Following Meeting With FDA

Feb 14 (Reuters) - Omeros Corp <OMER.O>::OMEROS CORPORATION STREAMLINES PATH TO BIOLOGICS LICENSE APPLICATION FOR OMS721 IN HSCT-TMA FOLLOWING MEETING WITH FDA.OMEROS CORP - HAS STREAMLINED REQUIRED WORK AND FURTHER ADVANCED ITS PREPARATIONS FOR ITS BIOLOGICS LICENSE APPLICATION FOR OMS721.OMEROS CORP - PATIENT DATA FROM EXISTING SINGLE-ARM STUDY WILL FORM BASIS FOR BLA; NO HISTORICAL CONTROL REQUIRED.OMEROS - PLANS TO MEET EUROPEAN REGULATORS, EXPECTS TO HARMONIZE MARKETING AUTHORIZATION APPLICATION FOR OMS721 IN HSCT-TMA IN EUROPE WITH U.S. BLA.OMEROS CORP - ENROLLING OMS721 PHASE 3 CLINICAL TRIALS FOR IMMUNOGLOBULIN A NEPHROPATHY & ATYPICAL HEMOLYTIC UREMIC SYNDROME.

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy

Jan 17 (Reuters) - Omeros Corp <OMER.O>::OMEROS FINALIZES WITH FDA CLINICAL PLAN FOR OMS721 APPROVAL IN IGA NEPHROPATHY.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL--.OMEROS CORP - ADDITIONAL POSITIVE DATA REPORTED FROM SECOND COHORT IN PHASE 2 TRIAL.OMEROS - OMS721 CONTINUES TO BE WELL TOLERATED AND NO SAFETY CONCERNS HAVE BEEN OBSERVED.OMEROS CORP - DURING FDA MEETING, IT WAS CONFIRMED THAT PHASE 3 TRIAL'S PRIMARY ENDPOINT OF ASSESSMENT OF PROTEINURIA WILL BE EXTENDED TO 36 WEEKS.

Omeros Corp Reports Preliminary Total And Omidria Q4 Revenues Of About $22 Mln

Jan 14 (Reuters) - Omeros Corp <OMER.O>::ORATION ANNOUNCES RECORD HIGH QUARTERLY REVENUE RESULTS FOR THE FOURTH QUARTER 2018.PRELIMINARY TOTAL AND OMIDRIA REVENUES FOR Q4 OF 2018 ARE EXPECTED TO BE A RECORD HIGH AT APPROXIMATELY $22.0 MILLION.DOES NOT CURRENTLY INTEND IN FUTURE TO MAKE PUBLIC PRELIMINARY SALES REVENUES ON A ROUTINE BASIS.Q4 PRELIMINARY ANNUALIZED RUN RATE OF WEEKLY NET SALES IN DECEMBER WAS ABOUT $100 MILLION.Q4 REVENUE VIEW $13.9 MILLION -- REFINITIV IBES DATA.

Omeros Corp Announces Clinical Strategy To Accelerate Pediatric Development Of OMS721

Dec 6 (Reuters) - Omeros Corp <OMER.O>::OMEROS ANNOUNCES CLINICAL STRATEGY TO ACCELERATE PEDIATRIC DEVELOPMENT OF OMS721 FOR THE TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA).OMEROS CORP - EMA CONFIRMED OMS721 ELIGIBILITY FOR EUROPEAN CENTRALIZED MARKETING AUTHORIZATION APPLICATION REVIEW.OMEROS - SUBMITTED PIP FOR USE OF OMS721 FOR TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) TO EMA.

Omeros Announces Proposed $210 Million Offering Of Convertible Senior Notes Due 2023

Omeros Corp <OMER.O>::OMEROS ANNOUNCES PROPOSED $210 MILLION OFFERING OF CONVERTIBLE SENIOR NOTES DUE 2023.OMEROS CORP - NOTES WILL MATURE ON NOVEMBER 15, 2023.OMEROS CORP-TO USE PORTION OF PROCEEDS OF OFFERING TO REPAY IN FULL AMOUNTS OUTSTANDING UNDER CO'S SECURED TERM LOAN AGREEMENT WITH CRG SERVICING LLC.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up